Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enviomycin
- Development stage
- Unknown
- Lead developer
- Asahi Kasei
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Parenteral (intramuscular Or Intravenous)
01
Overview
Enviomycin is a cyclic basic peptide antibiotic related to viomycin and classified as a tuberactinomycin. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus. Enviomycin acts as an antitubercular agent with less ototoxicity than other drugs in its class such as viomycin and capreomycin. Its primary use is for the treatment of tuberculosis, including pulmonary tuberculosis and infections caused by Mycobacterium avium complex[1][2][3][4][7]. The drug inhibits bacterial protein synthesis by binding to the 70S ribosome of susceptible mycobacteria[6]. It has been approved for clinical use in Japan since 1975 but does not have approval in the US or Europe[7].
- Brand names
- Tuberactin
- Other names
- enviomycinaenviomycineenviomycinumtuberactinomycin-N
02
Targets
70S ribosome (Bacterial protein synthesis ribosome complex)Neuraminidase
Beyond the preview
Go deeper on enviomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enviomycin.